Moleculin Biotech
MBRX
12 hedge funds and large institutions have $3.71M invested in Moleculin Biotech in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
9% more funds holding
Funds holding: 11 → 12 (+1)
2.58% less ownership
Funds ownership: 8.94% → 6.36% (-2.6%)
66% less capital inflows, than outflows
Capital inflows: $474K | Capital outflows: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$94.8K |
| 2 |
Renaissance Technologies
New York
|
+$94.8K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$94.8K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$47.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$47.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.19M |
| 2 |
BlackRock
New York
|
-$94.8K |
| 3 |
Two Sigma Securities
New York
|
-$55K |
| 4 |
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$44K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$22K |
MBRX Hedge Fund Activity: Q2 2020 in Review
12 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2020, worth a combined $3.71M — up 28% from $2.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MBRX positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $94.8K. The largest seller was Vanguard Group, cutting an estimated $1.19M.
- 12 institutional investors held Moleculin Biotech (MBRX) as of Q2 2020, up from 11 in Q1 2020.
- Funds reported $3.71M of Moleculin Biotech stock for Q2 2020, up 28% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q2 2020 and 3 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q2 2020 was Geode Capital Management, an estimated $94.8K added.
- The largest Moleculin Biotech seller in Q2 2020 was Vanguard Group, an estimated $1.19M sold.
Based on aggregated 13F filings for Q2 2020.